Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.

Autor: Ho So, Cheng, Isaac T., Sze-Lok Lau, Chow, Evelyn, Lam, Tommy, Hung, Vivian W., Li, Edmund K., Griffith, James F., Lee, Vivian W., Lin Shi, Junbin Huang, Kitty Yan Kwok, Cheuk-Wan Yim, Li, Tena K., Vincent Lo, Jolie Lee, Jack Jock-Wai Lee, Ling Qin, Lai-Shan Tam, So, Ho
Předmět:
Zdroj: Annals of the Rheumatic Diseases; Aug2021, Vol. 80 Issue 8, p981-988, 8p
Abstrakt: Objective: To evaluate the effects of denosumab on erosion healing at 2-4 metacarpophalangeal (MCP) head as determined by high-resolution peripheral quantitative CT (HR-pQCT) in patients with rheumatoid arthritis (RA) with stable disease.Methods: This was a randomised, placebo-controlled, double-blind study. Patients with RA with disease activity score 28 joints (DAS28) ≤5.1 were randomised (1:1) to subcutaneous denosumab 60 mg or placebo once every 6 months for 24 months. The primary outcome was erosion healing at MCP 2-4 on HR-pQCT at 12 months. The effects of denosumab on erosion and joint space parameters on HR-pQCT and radiographs, disease activity and health assessment questionnaire-disability index (HAQ-DI) were also examined.Results: At 24 months, HR-pQCT images were analysed in 98 patients. One-third of the patients achieved sustained low disease activity throughout the study. At 12 months, changes in erosion parameters on HR-pQCT were similar between the two groups. At 24 months, new erosions (19% vs 9%, p=0.009) and erosion progression (18% vs 8%, p=0.019) were more common in the placebo group than the denosumab group. Erosion healing was seen in a significantly higher proportion of patients in the denosumab group (20% vs 6%, p=0.045) at 24 months. No significant changes in joint space parameters on HR-pQCT, van der Heijde-Sharp erosion score, DAS28 and HAQ-DI were observed in the two groups at 12 and 24 months.Conclusion: Although no differences in erosion parameters were observed at 12 months, denosumab was more efficacious than placebo in erosion repair on HR-pQCT after 24 months.Trial Registration Number: NCT03239080. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index